Alimera Sciences, which announced a significant drug rights acquisition on Monday, said on Tuesday that it had closed on $30 million in C-round venture financing.

The funds will be used for the deal it struck on Monday with Medidur FA, an Australian drug and medical device company as well as continued development of the drug.

Intersouth Partners in Durham, N.C. participated in the C round. It is one of the original investors in Alimera. In 2006, Alimera raised a B round of more than $31 million.

In a revision of an earlier agreement, Alimera will pay pSivida a $12 million upfront payment. Other payments totaling as much as an additional $66 million could be earned by pSivida if the drug known as Medidur secures U.S. Food and Drug Administration approval. As part of the deal Alimera will assume $20 million in research and development costs.

Medidur is intended to be a treatment for diabetic macular edema (DME). It is currently in Phase III clinical trials. The side effect of diabetes causes swelling and loss of vision.

The new deal gives Alimera an 80 percent share of profits for Medidur, up from 50 percent.

DME affects up to 200,000 people a year, and there is no FDA approved treatment.

Last September, Alimera reached an agreement with Emory University researchers on potential eye treatments.